Colchicine in Patients with Chronic Coronary Disease
Abstract
This multicenter randomized controlled trial (LoDoCo2) investigated the efficacy of low-dose colchicine (0.5 mg once daily) versus placebo in reducing cardiovascular events in 5522 patients with stable chronic coronary disease. Over a median follow-up of 28.6 months, colchicine significantly lowered the risk of the primary composite endpoint—cardiovascular death, nonprocedural myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization (6.8% vs. 9.6%; HR: 0.69; P<0.001). Secondary endpoints, including cardiovascular death, myocardial infarction, and stroke, also favored colchicine. While rates of noncardiovascular death were numerically higher in the colchicine group, this difference was not statistically significant (HR: 1.51; 95% CI: 0.99–2.31). The treatment effect was consistent across most clinical subgroups. Adverse events such as myalgia were more commonly reported in the colchicine arm, though serious toxicities were rare. The study supports colchicine as an effective adjunct for reducing residual cardiovascular risk in patients already on standard secondary prevention therapies.
Keywords:
chronic coronary disease
colchicine
cardiovascular events
randomized trial
LoDoCo2
inflammation
myocardial infarction
revascularization
Article Document
1 / 1
100%